ENTA - Enanta Pharmaceuticals, Inc.
| Previous Close | 103.15 |
| Open | 105.00 |
| Bid | 24.44 x 1100 |
| Ask | 198.00 x 1100 |
| Day's Range | 98.29 - 106.23 |
| 52 Week Range | 64.08 - 127.77 |
| Volume | 667,206 |
| Avg. Volume | 291,111 |
| Market Cap | 1.968B |
| Beta (3Y Monthly) | 1.40 |
| PE Ratio (TTM) | 24.53 |
| EPS (TTM) | 4.13 |
| Earnings Date | May 7, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 99.50 |
- GlobeNewswire•5 days ago
Factors of Influence in 2019, Key Indicators and Opportunity within BCE, Nektar Therapeutics, Hormel Foods, Enanta Pharmaceuticals, MongoDB, and Regal Beloit — New Research Emphasizes Economic Growth
NEW YORK, Feb. 15, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Thomson Reuters StreetEvents•9 days ago
Edited Transcript of ENTA earnings conference call or presentation 6-Feb-19 9:30pm GMT
Q1 2019 Enanta Pharmaceuticals Inc Earnings Call
Motley Fool•13 days agoEnanta Pharmaceuticals Inc (ENTA) Q1 2019 Earnings Conference Call Transcript
ENTA earnings call for the period ending December 31, 2018.
- Zacks•14 days ago
Enanta Pharmaceuticals (ENTA) Lags Q1 Earnings and Revenue Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -14.38% and -4.34%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•14 days ago
Enanta Pharmaceuticals: Fiscal 1Q Earnings Snapshot
The Watertown, Massachusetts-based company said it had net income of $1.25 per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
- Business Wire•14 days ago
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter and Three Months Ended December 31, 2018
Webcast and Conference Call today at 4:30 p.m. ET
- Zacks•21 days ago
Enanta Pharmaceuticals (ENTA) Earnings Expected to Grow: Should You Buy?
Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.•29 days ago
Do You Like Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) At This P/E Ratio?
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). To keep it practical, we'll show how Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Read More...
- Business Wire•29 days ago
Enanta Pharmaceuticals to Host Conference Call on February 6th at 4:30 pm ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2018
Enanta Pharmaceuticals, Inc. (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2018 after the U.S. markets close on February 6, 2019. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s business, including its research and development pipeline. Enanta will host a conference call and webcast on February 6 at 4:30 p.m. ET.
- Thomson Reuters StreetEvents•last month
Edited Transcript of ENTA earnings conference call or presentation 26-Nov-18 9:30pm GMT
Q4 2018 Enanta Pharmaceuticals Inc Earnings Call
- Business Wire•2 months ago
Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Business Outlook for 2019 during the 37th Annual J.P. Morgan Healthcare Conference
Enanta Pharmaceuticals, Inc. (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., Enanta’s President and Chief Executive Officer, will provide an update on its research and development programs in respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH)/primary biliary cholangitis (PBC), and discuss its business outlook for 2019 during Enanta’s presentation at the 37th Annual J.P. Morgan Healthcare Conference on January 7, 2019 at 4:30 p.m. Pacific time.
- Business Wire•2 months ago
Enanta Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
Enanta Pharmaceuticals, Inc. (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., Enanta’s President and Chief Executive Officer will make a formal presentation at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 4:30 p.m. Pacific Time. The presentation will contain a business overview and an update on Enanta’s research and development programs.
- Insider Monkey•2 months ago
Here is What Hedge Funds Think About Enanta Pharmaceuticals Inc (ENTA)
Is Enanta Pharmaceuticals Inc (NASDAQ:ENTA) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy league graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage […]
- Simply Wall St.•3 months ago
Is Enanta Pharmaceuticals Inc’s (NASDAQ:ENTA) CEO Pay Fair?
Jay Luly has been the CEO of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) since 2003. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then Read More...
- GuruFocus.com•3 months ago
Enanta Pharmaceuticals Inc (ENTA) Files 10-K for the Fiscal Year Ended on September 30, 2018
Warning! GuruFocus has detected 4 Warning Signs with ENTA. For the last quarter Enanta Pharmaceuticals Inc reported a revenue of $67.2 million, compared with the revenue of $75.93 million during the same period a year ago. For the last five years Enanta Pharmaceuticals Inc had an average revenue growth rate of 37% a year.
Motley Fool•3 months agoEnanta Pharmaceuticals Inc (ENTA) Q4 2018 Earnings Conference Call Transcript
ENTA earnings call for the period ending September 30, 2018.
- Associated Press•3 months ago
Enanta Pharmaceuticals: Fiscal 4Q Earnings Snapshot
The Watertown, Massachusetts-based company said it had profit of $1.30 per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
- Business Wire•3 months ago
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2018
Webcast and Conference Call today at 4:30 p.m. ET
- Zacks•3 months ago
Enanta Pharmaceuticals (ENTA) Expected to Beat Earnings Estimates: Should You Buy?
Enanta Pharmaceuticals (ENTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire•3 months ago
Enanta Announces that AbbVie’s MAVYRET™ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis
Enanta Announces that AbbVie’s MAVYRET™ Shows High Virologic Cure Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis
- PR Newswire•3 months ago
AbbVie's MAVYRET™ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis
NORTH CHICAGO, Ill., Nov. 13, 2018 /PRNewswire/ -- AbbVie (ABBV), a research-based global biopharmaceutical company, today announced new data for its pan-genotypic chronic hepatitis C virus (HCV) treatment, MAVYRET™ (glecaprevir/pibrentasvir), in treatment-naïve patients with compensated cirrhosis.
- Zacks•3 months ago
Why the Earnings Surprise Streak Could Continue for Enanta Pharmaceuticals (ENTA)
Enanta Pharmaceuticals (ENTA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Business Wire•4 months ago
Enanta Pharmaceuticals to Host Conference Call on November 26 at 4:30 pm ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2018
Enanta Pharmaceuticals, Inc. (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal fourth quarter and fiscal year ended September 30, 2018, after the U.S. markets close on November 26, 2018. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s business, including its research and development pipeline. Enanta will host a conference call and webcast on November 26 at 4:30 p.m. ET.
- Business Wire•4 months ago
Enanta Pharmaceuticals Announces Positive Phase 1 Results and Initiation of Phase 2a Clinical Study of EDP-938 for Respiratory Syncytial Virus
Enanta Pharmaceuticals, Inc. (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that dosing has begun in a Phase 2a study to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of orally administered EDP-938 against respiratory syncytial virus infection in a human challenge study. “RSV is an infection for which there is no safe and effective treatment,” stated Jay R. Luly, Ph.D., President and CEO, Enanta. “Infants, the elderly, and immune compromised individuals are at the highest risk for this severe respiratory tract infection.
